CONCENTRATINON OF ANTI – ANGIOGENIC FACTOR INPREGNANT WOMEN IN THE FIRST TRIMESTER OF PREGNANCY MANAGEMENT OF TEMPLE AT THAI NGUYEN NATIONAL HOSPITAL

Lê Thị Hương Lan; Lê Thị Minh Hiền; Nông Thị Đương

doi:10.34238/tnu-jst.6718

CONCENTRATINON OF ANTI – ANGIOGENIC FACTOR INPREGNANT WOMEN IN THE FIRST TRIMESTER OF PREGNANCY MANAGEMENT OF TEMPLE AT THAI NGUYEN NATIONAL HOSPITAL

About this article

Received: 18/10/22 Revised: 20/12/22 Published: 27/12/22

Authors

1. Le Thi Huong Lan , Thai Nguyen National Hospital
2. Le Thi Minh Hien, TNU - University of Medicine and Pharmacy
3. Nong Thi Duong, Thai Nguyen National Hospital

Abstract

To determine the concentration of PLGF and SFlt-1 in pregnant women in the first trimester of pregnancy in Thai Nguyen, the study was carried out on 201 pregnant women at high risk of preeclampsia, and 200 normal pregnant women with gestational age from 11 weeksup to 13 weeks and 6 days, using cross-sectional descriptive research method. PLGF and SFlt-1 concentrations were measured by chemiluminescence electrochemical method using Roche dianostig reagent. The result showed that: the concentration of PlGF, sFlt-1, the ratio sFlt-1/PlGF in normal pregnant women with gestational age from 11-13 weeks and 6 days are: 70.3 pg/dl; 1371.5 pg/dl and 18.4. The concentration of PlGF, sFlt-1, the ratio sFlt-1/PlGF in normal pregnant women in our study are different from the reference values recommended by Roche for normal pregnant women at 10-14 weeks gestation. In which, the concentration of PlGF, sFlt-1 was higher, whereas the ratio sFlt-1/PlGF was lower than the reference value of Roche (p<0.05). Pregnant women at risk of pre-eclampsia at the same gestational age: the PLGF level was 52.5 pg/dl; Sflt1: 1678, 9 pg/dl; the sFlt-1/PlGF ratio is 28.9. The concentration of PlGF decreased, the concentration of sFlt-1 and especially the ratio sFlt-1/PlGF increased compared to the concentration and ratio of these factors in normal pregnant women with corresponding gestational age (p<0.001).

Keywords

Preeclampsia; PLGF; SFlt-1 levels; Screening; First trimester of pregnancy

Full Text:

PDF (Tiếng Việt)

References

[1] V. B. Nguyen and D. C. Tran, Review on the treatment of pregnancy toxicity on 83 patients at the obstetrics department I of the Institute for the Protection of Mothers and Newborns, Scientific research work, Institute for the Protection of Mothers and Newborns, pp. 52-57, 1998.

[2] L. C. Poon et al., “The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention,” Ultrasound Obstet ynecol, vol. 55, pp. 5-12, 2020.

[3] A. De Vivo, G. Baviera, and D. Giordano, “Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia,” Acta ObstetGynecol, vol. 87, pp. 837-842, 2008.

[4] V. Stefan, G. Alberto, S. Dietmar, Z. Harald, H. Ignacio, G. Manfred, P. Juliane, W. Joachim, D. Barbara, and S. Holger, “An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia,” American Journal of Obstetrics & Gynecology, vol. 202, no. 2, pp. 161.e1-161.e11, 2010.

[5] J. Schiettecatte, H. Russcher, E. Anckaert, M. Mees, B. Leeser, A. S. Tirelli, G. M. Fiedler, H. Luthe, B. Denk, and J. Smitz, “Multicenter evaluation of the ﬁrst automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia,” Clinical Biochemistry, vol. 43, pp. 768-770, 2010.

[6] M. Tjwa, A. Luttun, M. Autiero, and P. Carmeliet, “VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis,” Cell Tissue Res, vol. 314, pp. 5-14, 2003.

[7] R. Akolekar, A. Syngelaki, R. Sarquis, M. Zvanca, and K. H. Nicolaides, “Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks,” PrenatDiagn., vol. 31, no. 1, pp. 66-74, 2011.

[8] B. K. Ambati, M. Nozaki, N. Singh, A. Takeda, P. D. Jani, T. Suthar, R. J. Albuquerque, E. Richter, E. Sakurai, M. T. Newcomb, M. E. Kleinman, R. B. Caldwell, Q. Lin, Y. Ogura, A. Orecchia, D. A. Samuelson, D. W. Agnew, and J. St. Leger, “Cornealavascularity is due to soluble VEGF receptor-1,” Nature, vol. 443, pp. 993-997, 2006.

[9] S. Verlohrena, S. P. Brennecke et al., “Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia,” Am J Obstet Gynecol, vol. 226, no. 2S, pp. S1071-S1097.e2, 2022.

[10] J. H. Lim, S. Y. Kim, S. Y. Park, J. H. Yang, M. Y. Kim, and H. M. Ryu, "Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors,” ObstetGynecol, vol. 111, no. 6, pp. 1403-1409, 2008.

[11] S. Hahn, A. K. Gupta, C. Troeger, C. Rusterholz, and W. Holzgreve, “Disturbances in placental immunology: ready for therapeutic interventions?” Springer Semin Immunopathol, vol. 27, pp. 477-493, 2006.

DOI: https://doi.org/10.34238/tnu-jst.6718

Refbacks

There are currently no refbacks.



Remember me